BOSTON SCIENTIFIC CORP (BSX.DE) Stock Fundamental Analysis
Europe - FRA:BSX - US1011371077 - Common Stock
88.2 EUR
+1.6 (+1.85%)
BSX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 60 industry peers in the Health Care Equipment & Supplies industry. BSX has an average financial health and profitability rating. BSX is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
BSX had positive earnings in the past year.
In the past year BSX had a positive cash flow from operations.
Of the past 5 years BSX 4 years were profitable.
In the past 5 years BSX always reported a positive cash flow from operatings.
1.2 Ratios
BSX's Return On Assets of 6.03% is fine compared to the rest of the industry. BSX outperforms 71.67% of its industry peers.
Looking at the Return On Equity, with a value of 11.17%, BSX is in the better half of the industry, outperforming 71.67% of the companies in the same industry.
BSX has a better Return On Invested Capital (7.66%) than 66.67% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BSX is below the industry average of 8.99%.
The last Return On Invested Capital (7.66%) for BSX is above the 3 year average (6.54%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.03% | ||
| ROE | 11.17% | ||
| ROIC | 7.66% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
1.3 Margins
The Profit Margin of BSX (13.54%) is better than 78.33% of its industry peers.
In the last couple of years the Profit Margin of BSX has declined.
Looking at the Operating Margin, with a value of 18.69%, BSX belongs to the top of the industry, outperforming 85.00% of the companies in the same industry.
In the last couple of years the Operating Margin of BSX has remained more or less at the same level.
With a decent Gross Margin value of 68.30%, BSX is doing good in the industry, outperforming 78.33% of the companies in the same industry.
In the last couple of years the Gross Margin of BSX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.69% | ||
| PM (TTM) | 13.54% | ||
| GM | 68.3% |
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
2. Health
2.1 Basic Checks
BSX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, BSX has more shares outstanding
Compared to 5 years ago, BSX has more shares outstanding
The debt/assets ratio for BSX is higher compared to a year ago.
2.2 Solvency
BSX has an Altman-Z score of 5.66. This indicates that BSX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.66, BSX belongs to the top of the industry, outperforming 90.00% of the companies in the same industry.
BSX has a debt to FCF ratio of 3.33. This is a good value and a sign of high solvency as BSX would need 3.33 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.33, BSX is in the better half of the industry, outperforming 70.00% of the companies in the same industry.
A Debt/Equity ratio of 0.50 indicates that BSX is not too dependend on debt financing.
The Debt to Equity ratio of BSX (0.50) is worse than 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 3.33 | ||
| Altman-Z | 5.66 |
ROIC/WACC0.92
WACC8.29%
2.3 Liquidity
BSX has a Current Ratio of 1.37. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
BSX has a Current ratio of 1.37. This is comparable to the rest of the industry: BSX outperforms 46.67% of its industry peers.
A Quick Ratio of 0.82 indicates that BSX may have some problems paying its short term obligations.
The Quick ratio of BSX (0.82) is worse than 61.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.37 | ||
| Quick Ratio | 0.82 |
3. Growth
3.1 Past
BSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.00%, which is quite impressive.
The Earnings Per Share has been growing by 9.56% on average over the past years. This is quite good.
Looking at the last year, BSX shows a very strong growth in Revenue. The Revenue has grown by 21.62%.
BSX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.30% yearly.
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
3.2 Future
Based on estimates for the next years, BSX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.01% on average per year.
BSX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.51% yearly.
EPS Next Y22.11%
EPS Next 2Y18.06%
EPS Next 3Y16.46%
EPS Next 5Y15.01%
Revenue Next Year20.9%
Revenue Next 2Y16.08%
Revenue Next 3Y14.18%
Revenue Next 5Y12.51%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BSX is valuated quite expensively with a Price/Earnings ratio of 34.59.
BSX's Price/Earnings ratio is in line with the industry average.
BSX's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 26.34.
BSX is valuated quite expensively with a Price/Forward Earnings ratio of 29.18.
BSX's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 34.43. BSX is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.59 | ||
| Fwd PE | 29.18 |
4.2 Price Multiples
BSX's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. BSX is more expensive than 63.33% of the companies in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as BSX.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 43.42 | ||
| EV/EBITDA | 34.02 |
4.3 Compensation for Growth
BSX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
BSX has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as BSX's earnings are expected to grow with 16.46% in the coming years.
PEG (NY)1.56
PEG (5Y)3.62
EPS Next 2Y18.06%
EPS Next 3Y16.46%
5. Dividend
5.1 Amount
BSX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:BSX (11/11/2025, 7:00:00 PM)
88.2
+1.6 (+1.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners93.27%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap130.69B
Revenue(TTM)19.35B
Net Income(TTM)2.50B
Analysts86.34
Price Target110.26 (25.01%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.53%
Min EPS beat(2)2.49%
Max EPS beat(2)10.56%
EPS beat(4)4
Avg EPS beat(4)6.23%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.12%
EPS beat(12)11
Avg EPS beat(12)5.14%
EPS beat(16)15
Avg EPS beat(16)4.28%
Revenue beat(2)2
Avg Revenue beat(2)1.7%
Min Revenue beat(2)0.97%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)2.15%
Min Revenue beat(4)0.97%
Max Revenue beat(4)3.16%
Revenue beat(8)8
Avg Revenue beat(8)2.1%
Revenue beat(12)11
Avg Revenue beat(12)2.01%
Revenue beat(16)12
Avg Revenue beat(16)1.41%
PT rev (1m)1.6%
PT rev (3m)5.17%
EPS NQ rev (1m)0.11%
EPS NQ rev (3m)-0.04%
EPS NY rev (1m)1.77%
EPS NY rev (3m)3.98%
Revenue NQ rev (1m)0.24%
Revenue NQ rev (3m)0.22%
Revenue NY rev (1m)0.99%
Revenue NY rev (3m)1.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.59 | ||
| Fwd PE | 29.18 | ||
| P/S | 8.18 | ||
| P/FCF | 43.42 | ||
| P/OCF | 35.31 | ||
| P/B | 6.75 | ||
| P/tB | N/A | ||
| EV/EBITDA | 34.02 |
EPS(TTM)2.55
EY2.89%
EPS(NY)3.02
Fwd EY3.43%
FCF(TTM)2.03
FCFY2.3%
OCF(TTM)2.5
OCFY2.83%
SpS10.78
BVpS13.07
TBVpS-1.7
PEG (NY)1.56
PEG (5Y)3.62
Graham Number27.38
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.03% | ||
| ROE | 11.17% | ||
| ROCE | 9.51% | ||
| ROIC | 7.66% | ||
| ROICexc | 7.77% | ||
| ROICexgc | 26.52% | ||
| OM | 18.69% | ||
| PM (TTM) | 13.54% | ||
| GM | 68.3% | ||
| FCFM | 18.84% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
ROICexc(3y)6.7%
ROICexc(5y)5.9%
ROICexgc(3y)22.68%
ROICexgc(5y)19.43%
ROCE(3y)8.12%
ROCE(5y)7.05%
ROICexgc growth 3Y8.56%
ROICexgc growth 5Y6.81%
ROICexc growth 3Y4.36%
ROICexc growth 5Y5.23%
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
F-Score5
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 3.33 | ||
| Debt/EBITDA | 2.33 | ||
| Cap/Depr | 60.84% | ||
| Cap/Sales | 4.33% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 89.77% | ||
| Profit Quality | 139.08% | ||
| Current Ratio | 1.37 | ||
| Quick Ratio | 0.82 | ||
| Altman-Z | 5.66 |
F-Score5
WACC8.29%
ROIC/WACC0.92
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
EPS Next Y22.11%
EPS Next 2Y18.06%
EPS Next 3Y16.46%
EPS Next 5Y15.01%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
Revenue Next Year20.9%
Revenue Next 2Y16.08%
Revenue Next 3Y14.18%
Revenue Next 5Y12.51%
EBIT growth 1Y26.44%
EBIT growth 3Y12.47%
EBIT growth 5Y10.54%
EBIT Next Year35.51%
EBIT Next 3Y19.85%
EBIT Next 5Y17.37%
FCF growth 1Y131.03%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y101.7%
OCF growth 3Y22.44%
OCF growth 5Y13.34%
BOSTON SCIENTIFIC CORP / BSX.DE FAQ
What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to BSX.DE.
What is the valuation status of BOSTON SCIENTIFIC CORP (BSX.DE) stock?
ChartMill assigns a valuation rating of 2 / 10 to BOSTON SCIENTIFIC CORP (BSX.DE). This can be considered as Overvalued.
How profitable is BOSTON SCIENTIFIC CORP (BSX.DE) stock?
BOSTON SCIENTIFIC CORP (BSX.DE) has a profitability rating of 6 / 10.
Can you provide the financial health for BSX stock?
The financial health rating of BOSTON SCIENTIFIC CORP (BSX.DE) is 4 / 10.
What is the expected EPS growth for BOSTON SCIENTIFIC CORP (BSX.DE) stock?
The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (BSX.DE) is expected to grow by 22.11% in the next year.